Ivabradine - The beauty of a slow heart rate

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 542-546

  Khawaja, M Z ^a   Walker, D M ^a  

^a East Sussex Healthcare NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CALCIUM CHANNEL; ION CHANNEL; IVABRADINE;

ADRENERGIC STIMULATION; CHRONIC DISEASE; CORONARY ARTERY BLOOD FLOW; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SINUS BRADYCARDIA; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; VISUAL DISORDER;

ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; HEART DISEASES; HEART RATE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 62749203968     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02005.x     Document Type: Review

References (43)

1. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J, 1987 113 : 1489 94.
2. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J, 1991 1 : 172 7.
3. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension, 1999 33 : 44 52.
4. Seccareccia F, Pannozzo F, Dima F et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health, 2001 91 : 1258 63.
5. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J, 2005 26 : 967 74.
6. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J, 2008 29 : 1327 34.
7. Grassi G, Vailati S, Bertinieri G et al. Heart rate as marker of sympathetic activity. J Hypertens, 1998 16 : 1635 9.
8. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension, 1993 21 : 618 23.
9. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol, 2008 126 : 302 12.
10. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation, 2001 104 : 1477 82.
11. Colin P, Ghaleh B, Monnet X et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol, 2003 284 : H676 82.
12. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther, 2004 308 : 236 40.
13. Ferrari R. Selective heart rate reduction: a new approach to the management of angina pectoris. Medicographia, 2002 24 : 207 10.
14. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol, 1986 57 : 43F 9F.
15. Infarction", T.D.S.G.o.V.i.M. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Am J Cardiol, 1990 66 : 33I 40I.
16. Theroux P, Grégoire J, Chin C, Pelletier G, de Guise P, Juneau M. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol, 1998 32 : 620 8.
17. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovasc Drugs Ther, 1991 4 (Suppl. 6 1229 32.
18. Ramahi TM. Beta blocker therapy for chronic heart failure. Am Fam Physician, 2000 62 : 2267 74.
19. Lewis RV. Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf, 1993 9 : 272 9.
20. investigators C.-I. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 1999 353 : 9 13.
21. Hjalmarson A et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA, 2000 283 : 1295 302.
22. Mahon N, McKenna WJ. Calcium channel blockers in cardiac failure. Prog Cardiovasc Dis, 1998 41 : 191 206.
23. DiFrancesco D. A new interpretation of the pacemaker current in calf Purkinje fibres. J Physiol, 1981 314 : 359 76.
24. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature, 1979 280 : 235 6.
25. DiFrancesco D, Mangoni M. Modulation of single hyperpolarization- activated channels (i(f)) by cAMP in the rabbit sino-atrial node. J Physiol, 1994 474 : 473 82.
26. Vilaine J-P, P J-L. The discovery of the If current inhibitor Procorolan. Medicographia, 2005 27 : 67 74.
27. Purcell H, F K. Selective and specific If inhibition: new perspectives. Medicographia, 2005 27 : 51 4.
28. JS B. If inhibition as a therapeutic approach in stable angina: experimental and clinical studies. Medicographia, 2005 27 : 44 50.
29. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol, 1996 118 : 1051 7.
30. Vilaine JP, Bidouard JP, Lesage L, Reure H, Péglion JL. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol, 2003 42 : 688 96.
31. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther, 1998 64 : 192 203.
32. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D, 2003 4 : 83 9.
33. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin, 2005 21 : 1115 22.
34. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J, 2005 26 : 2529 36.
35. Fox KM, T J, Ford M, Tendera M. Anti-anginal and anti-ischaemic efficacy of ivabradine - a selective and specific sinus node If current inhibitor - compared to atenolol in elderly patients with chronic stable angina. Heart, 2005 91 (suppl 1 A69.
36. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs, 2007 67 : 393 405.
37. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation, 2003 107 : 817 23.
38. Tardif JC. Clinical efficacy of ivabradine. Heart Drug, 2005 5 : 25 8.
39. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, 2008 372 : 807 16.
40. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, 2008 372 : 817 21.
41. Cleland JG et al. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther, 2004 18 : 139 52.
42. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000 342 : 145 53.
43. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003 362 : 782 8.